✦ LIBER ✦

Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling

✍ Scribed by Marinela Capanu; Patrick Concannon; Robert W. Haile; Leslie Bernstein; Kathleen E. Malone; Charles F. Lynch; Xiaolin Liang; Sharon N. Teraoka; Anh T. Diep; Duncan C. Thomas; Jonine L. Bernstein; The WECARE Study Collaborative Group; Colin B. Begg

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 139 KB
Volume: 35
Category: Article
ISSN: 0741-0395
DOI: 10.1002/gepi.20587

No coin nor oath required. For personal study only.

✦ Synopsis

Current evidence suggests that the genetic risk of breast cancer may be caused primarily by rare variants. However, while classification of protein-truncating mutations as deleterious is relatively straightforward, distinguishing as deleterious or neutral the large number of rare missense variants is a difficult on-going task. In this article, we present one approach to this problem, hierarchical statistical modeling of data observed in a case-control study of contralateral breast cancer (CBC) in which all the participants were genotyped for variants in BRCA1 and BRCA2. Hierarchical modeling permits leverage of information from observed correlations of characteristics of groups of variants with case-control status to infer with greater precision the risks of individual rare variants. A total of 181 distinct rare missense variants were identified among the 705 cases with CBC and the 1,398 controls with unilateral breast cancer. The model identified three bioinformatic hierarchical covariates, align-GV, align-GD, and SIFT scores, each of which was modestly associated with risk. Collectively, the 11 variants that were classified as adverse on the basis of all the three bioinformatic predictors demonstrated a stronger risk signal. This group included five of six missense variants that were classified as deleterious at the outset by conventional criteria. The remaining six variants can be considered as plausibly deleterious, and deserving of further investigation (BRCA1 R866C; BRCA2 G1529R, D2665G, W2626C, E2663V, and R3052W). Hierarchical modeling is a strategy that has promise for interpreting the evidence from future association studies that involve sequencing of known or suspected cancer genes. Genet. Epidemiol. 35:389-397, 2011.

📜 SIMILAR VOLUMES

A review of a multifactorial probability

A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)

✍ Noralane M. Lindor; Lucia Guidugli; Xianshu Wang; Maxime P. Vallée; Alvaro N. A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB 👁 1 views

Clinical mutation screening of the BRCA1 and BRCA2 genes for the presence of germline inactivating mutations is used to identify individuals at elevated risk of breast and ovarian cancer. Variants identified during screening are usually classified as pathogenic (increased risk of cancer) or not path

Classification of missense variants of u

Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information

✍ A. Osorio; R.L. Milne; E. Honrado; A. Barroso; O. Diez; R. Salazar; M. de la Hoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

Classification of rare missense variants in disease susceptibility genes as neutral or disease-causing is important for genetic counseling. Different criteria are used to help classify such variants in BRCA1 and BRCA2; however, the strongest evidence tends to come from segregation analysis and obser

Splicing and multifactorial analysis of

Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary

✍ Phillip J. Whiley; Lucia Guidugli; Logan C. Walker; Sue Healey; Bryony A. Thomps 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 1 views

Clinical management of breast cancer families is complicated by identification of BRCA1 and BRCA2 sequence alterations of unknown significance. Molecular assays evaluating the effect of intronic variants on native splicing can help determine their clinical relevance. Twentysix intronic BRCA1/2 varia

A yeast recombination assay to character

A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance

✍ Maria Adelaide Caligo; Fabrizia Bonatti; Lucia Guidugli; Paolo Aretini; Alvaro G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

The BRCA1 tumor suppressor gene is found mutated in familial breast cancer. Although many of the mutations are clearly pathological because they give rise to truncated proteins, several missense variants of uncertain pathological consequences have been identified. A novel functional assay to screen

Bayes analysis provides evidence of path

Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance

✍ Amanda B. Spurdle; Sunil R. Lakhani; Leonard M. Da Silva; Rosemary L. Balleine; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Although in vitro splicing assays can provide useful information about the clinical interpretation of sequence variants in high-risk cancer genes such as BRCA1 and BRCA2, results can sometimes be difficult to interpret. The BRCA1 c.135-1G>T (IVS3-1G>T) variant has been shown to give rise to an in-fr